Advertisement

Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study

      Abstract

      Background

      Nalmefene is a µ and δ opioid receptor antagonist, κ opioid receptor partial agonist that has recently been approved in Europe for treating alcohol dependence. It offers a treatment approach for alcohol-dependent individuals with “high-risk drinking levels” to reduce their alcohol consumption. However, the neurobiological mechanism underpinning its effects on alcohol consumption remains to be determined. Using a randomized, double-blind, placebo-controlled, within-subject crossover design we aimed to determine the effect of a single dose of nalmefene on striatal blood oxygen level–dependent (BOLD) signal change during anticipation of monetary reward using the monetary incentive delay task following alcohol challenge.

      Methods

      Twenty-two currently heavy-drinking, non–treatment-seeking alcohol-dependent males were recruited. The effect of single dose nalmefene (18 mg) on changes in a priori defined striatal region of interest BOLD signal change during reward anticipation compared with placebo was investigated using functional magnetic resonance imaging. Both conditions were performed under intravenous alcohol administration (6% vol/vol infusion to achieve a target level of 80 mg/dL).

      Results

      Datasets from 18 participants were available and showed that in the presence of the alcohol infusion, nalmefene significantly reduced the BOLD response in the striatal region of interest compared with placebo. Nalmefene did not alter brain perfusion.

      Conclusions

      Nalmefene blunts BOLD response in the mesolimbic system during anticipation of monetary reward and an alcohol infusion. This is consistent with nalmefene’s actions on opioid receptors, which modulate the mesolimbic dopaminergic system, and provides a neurobiological basis for its efficacy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nutt D.J.
        • King L.A.
        • Phillips L.D.
        • Independent Scientific Committee on Drugs
        Drug harms in the UK: A multicriteria decision analysis.
        Lancet. 2010; 376: 1558-1565
        • Grant B.F.
        • Goldstein R.B.
        • Saha T.D.
        • Chou S.P.
        • Jung J.
        • Zhang H.
        • et al.
        Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III.
        JAMA Psychiatry. 2015; 72: 757-766
        • Lingford-Hughes A.R.
        • Welch S.
        • Peters L.
        • Nutt D.J.
        • British Association for Psychopharmacology, Expert Reviewers Group
        BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP.
        J Psychopharmacol. 26. 2012: 899-952
        • Jonas D.E.
        • Amick H.R.
        • Feltner C.
        • Bobashev G.
        • Thomas K.
        • Wines R.
        • et al.
        Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis.
        JAMA. 2014; 311: 1889-1900
        • National Institute for Health and Care Excellence
        Nalmefene for reducing alcohol consumption in people with alcohol dependence. 2014; (Accessed January 15, 2017)
        • World Health Organization
        International Guide for Monitoring Alcohol Consumption and Related Harm. 2000; (http://apps.who.int/iris/bitstream/10665/66529/1/WHO_MSD_MSB_00.4.pdf. Accessed January 15, 2017)
        • van den Brink W.
        • Sorensen P.
        • Torup L.
        • Mann K.
        • Gual A.
        Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
        J Psychopharmacol. 2014; 28: 733-744
        • Gual A.
        • He Y.
        • Torup L.
        • van den Brink W.
        • Mann K.
        A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
        Eur Neuropsychopharmacol. 2013; 23: 1432-1442
        • Mann K.
        • Bladstrom A.
        • Torup L.
        • Gual A.
        • van den Brink W.
        Extending the treatment options in alcohol dependence: A randomized controlled study of as-needed nalmefene.
        Biol Psychiatry. 2013; 73: 706-713
        • Johnson S.W.
        • North R.A.
        Opioids excite dopamine neurons by hyperpolarization of local interneurons.
        J Neurosci. 1992; 12: 483-488
        • Pickel V.M.
        • Chan J.
        • Sesack S.R.
        Cellular basis for interactions between catecholaminergic afferents and neurons containing leu-enkephalin-like immunoreactivity in rat caudate-putamen nuclei.
        J Neurosci Res. 1992; 31: 212-230
        • Gracy K.N.
        • Svingos A.L.
        • Pickel V.M.
        Dual ultrastructural localization of mu-opioid receptors and NMDA-type glutamate receptors in the shell of the rat nucleus accumbens.
        J Neurosci. 1997; 17: 4839-4848
        • Khachaturian H.
        • Lewis M.E.
        • Haber S.N.
        • Akil H.
        • Watson S.J.
        Proopiomelanocortin peptide immunocytochemistry in rhesus monkey brain.
        Brain Res Bull. 1984; 13: 785-800
        • Spanagel R.
        • Herz A.
        • Shippenberg T.S.
        The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study.
        J Neurochem. 1990; 55: 1734-1740
        • Mitchell J.M.
        • O’Neil J.P.
        • Janabi M.
        • Marks S.M.
        • Jagust W.J.
        • Fields H.L.
        Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens.
        Sci Transl Med. 2012; 4: 116ra6
        • Heinz A.
        • Reimold M.
        • Wrase J.
        • Hermann D.
        • Croissant B.
        • Mundle G.
        • et al.
        Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: A positron emission tomography study using carbon 11-labeled carfentanil.
        Arch Gen Psychiatry. 2005; 62: 57-64
        • Williams T.M.
        • Daglish M.R.
        • Lingford-Hughes A.
        • Taylor L.G.
        • Hammers A.
        • Brooks D.J.
        • et al.
        Brain opioid receptor binding in early abstinence from opioid dependence: Positron emission tomography study.
        Br J Psychiatry. 2007; 191: 63-69
        • Williams T.M.
        • Davies S.J.
        • Taylor L.G.
        • Daglish M.R.
        • Hammers A.
        • Brooks D.J.
        • et al.
        Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study.
        Eur Neuropsychopharmacol. 2009; 19: 740-748
        • Ramchandani V.A.
        • Umhau J.
        • Pavon F.J.
        • Ruiz-Velasco V.
        • Margas W.
        • Sun H.
        • et al.
        A genetic determinant of the striatal dopamine response to alcohol in men.
        Mol Psychiatry. 2011; 16: 809-817
        • Bach P.
        • Vollsta Dt-Klein S.
        • Kirsch M.
        • Hoffmann S.
        • Jorde A.
        • Frank J.
        • et al.
        Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: A functional imaging study in alcohol dependent subjects.
        Eur Neuropsychopharmacol. 2015; 25: 1128-1135
        • Middaugh L.D.
        • Szumlinski K.K.
        • Van Patten Y.
        • Marlowe A.L.
        • Kalivas P.W.
        Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone.
        Alcohol Clin Exp Res. 2003; 27: 1892-1900
        • Lukas S.E.
        • Lowen S.B.
        • Lindsey K.P.
        • Conn N.
        • Tartarini W.
        • Rodolico J.
        • et al.
        Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: A bold FMRI study.
        Neuroimage. 2013; 78: 176-185
        • Myrick H.
        • Anton R.F.
        • Li X.
        • Henderson S.
        • Randall P.K.
        • Voronin K.
        Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
        Arch Gen Psychiatry. 2008; 65: 466-475
        • Volpicelli J.R.
        • Alterman A.I.
        • Hayashida M.
        • O’Brien C.P.
        Naltrexone in the treatment of alcohol dependence.
        Arch Gen Psychiatry. 1992; 49: 876-880
        • Ray L.A.
        • Hutchison K.E.
        Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study.
        Arch Gen Psychiatry. 2007; 64: 1069-1077
        • Stockwell T.
        • Sitharthan T.
        • McGrath D.
        • Lang E.
        The measurement of alcohol dependence and impaired control in community samples.
        Addiction. 1994; 89: 167-174
        • Miller W.R.
        • Sweben A.
        • DiClemente C.C.
        • Rychtarik R.G.
        The Drinker Inventory of Concequences (DrlnC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse.
        National Institutes of Health, Washington, DC1995
        • Sullivan J.T.
        • Sykora K.
        • Schneiderman J.
        • Naranjo C.A.
        • Sellers E.M.
        Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).
        Br J Addict. 1989; 84: 1353-1357
        • Sheehan D.V.
        • Lecrubier Y.
        • Sheehan K.H.
        • Amorim P.
        • Janavs J.
        • Weiller E.
        • et al.
        The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
        J Clin Psychiatry. 1998; 59: 22-33
        • Kyhl L.E.
        • Li S.
        • Faerch K.U.
        • Soegaard B.
        • Larsen F.
        • Areberg J.
        Population pharmacokinetics of nalmefene in healthy subjects and its relation to mu-opioid receptor occupancy.
        Br J Clin Pharmacol. 2016; 81: 290-300
        • Paterson L.M.
        • Flechais R.S.
        • Murphy A.
        • Reed L.J.
        • Abbott S.
        • Boyapati V.
        • et al.
        The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.
        J Psychopharmacol. 2015; 29: 943-960
        • O’Connor S.
        • Morzorati S.
        • Christian J.
        • Li T.K.
        Clamping breath alcohol concentration reduces experimental variance: Application to the study of acute tolerance to alcohol and alcohol elimination rate.
        Alcohol Clin Exp Res. 1998; 22: 202-210
        • Gan G.
        • Guevara A.
        • Marxen M.
        • Neumann M.
        • Junger E.
        • Kobiella A.
        • et al.
        Alcohol-induced impairment of inhibitory control is linked to attenuated brain responses in right fronto-temporal cortex.
        Biol Psychiatry. 2014; 76: 698-707
        • McGonigle J.
        • Murphy A.
        • Paterson L.M.
        • Reed L.J.
        • Nestor L.
        • Nash J.
        • et al.
        The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description.
        J Psychopharmacol. 2017; 31: 3-16
        • Cox R.W.
        AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages.
        Comput Biomed Res. 1996; 29: 162-173
        • Dale A.M.
        • Fischl B.
        • Sereno M.I.
        Cortical surface-based analysis. I. Segmentation and surface reconstruction.
        Neuroimage. 1999; 9: 179-194
        • Avants B.B.
        • Tustison N.J.
        • Song G.
        • Cook P.A.
        • Klein A.
        • Gee J.C.
        A reproducible evaluation of ANTs similarity metric performance in brain image registration.
        Neuroimage. 2011; 54: 2033-2044
        • Smith S.M.
        • Jenkinson M.
        • Woolrich M.W.
        • Beckmann C.F.
        • Behrens T.E.
        • Johansen-Berg H.
        • et al.
        Advances in functional and structural MR image analysis and implementation as FSL.
        Neuroimage. 2004; 23: S208-S219
        • Schott B.H.
        • Minuzzi L.
        • Krebs R.M.
        • Elmenhorst D.
        • Lang M.
        • Winz O.H.
        • et al.
        Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release.
        J Neurosci. 2008; 28: 14311-14319
        • Knutson B.
        • Adams C.M.
        • Fong G.W.
        • Hommer D.
        Anticipation of increasing monetary reward selectively recruits nucleus accumbens.
        J Neurosci. 2001; 21: RC159
        • Everitt B.J.
        • Robbins T.W.
        Neural systems of reinforcement for drug addition: From actions to habits to compulsion.
        Nat Neurosci. 2005; 8: 1481-1489
        • Everitt B.J.
        • Robbins T.W.
        From the ventral to the dorsal striatum: Devolving views of their roles in drug addiction.
        Neurosci Biobehav Rev. 2013; 37: 1946-1954
        • Sirohi S.
        • Bakalkin G.
        • Walker B.M.
        Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system.
        Front Mol Neurosci. 2012; 5: 95
        • Sjoerds Z.
        • Luigjes J.
        • van den Brink W.
        • Denys D.
        • Yucel M.
        The role of habits and motivation in human drug addiction: A reflection.
        Front Psychiatry. 2014; 5: 8
        • Beck A.
        • Schlagenhauf F.
        • Wustenberg T.
        • Hein J.
        • Kienast T.
        • Kahnt T.
        • et al.
        Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics.
        Biol Psychiatry. 2009; 66: 734-742
        • Wrase J.
        • Schlagenhauf F.
        • Kienast T.
        • Wustenberg T.
        • Bermpohl F.
        • Kahnt T.
        • et al.
        Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics.
        Neuroimage. 2007; 35: 787-794
        • Bjork J.M.
        • Smith A.R.
        • Hommer D.W.
        Striatal sensitivity to reward deliveries and omissions in substance dependent patients.
        Neuroimage. 2008; 42: 1609-1621
        • Bjork J.M.
        • Smith A.R.
        • Chen G.
        • Hommer D.W.
        Mesolimbic recruitment by nondrug rewards in detoxified alcoholics: Effort anticipation, reward anticipation, and reward delivery.
        Hum Brain Mapp. 2012; 33: 2174-2188
        • Andrews M.M.
        • Meda S.A.
        • Thomas A.D.
        • Potenza M.N.
        • Krystal J.H.
        • Worhunsky P.
        • et al.
        Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors.
        Biol Psychiatry. 2011; 69: 675-683
        • Nestor L.J.
        • Murphy A.
        • McGonigle J.
        • Orban C.
        • Reed L.
        • Taylor E.
        • et al.
        Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task [published online ahead of print Sep 6].
        Addict Biol. 2016;
        • Myrick H.
        • Anton R.F.
        • Li X.
        • Henderson S.
        • Drobes D.
        • Voronin K.
        • et al.
        Differential brain activity in alcoholics and social drinkers to alcohol cues: Relationship to craving.
        Neuropsychopharmacology. 2004; 29: 393-402
        • Benjamin D.
        • Grant E.R.
        • Pohorecky L.A.
        Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats.
        Brain Res. 1993; 621: 137-140
        • Spanagel R.
        • Herz A.
        • Shippenberg T.S.
        Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
        Proc Natl Acad Sci U S A. 1992; 89: 2046-2050
        • Emmerson P.J.
        • Liu M.R.
        • Woods J.H.
        • Medzihradsky F.
        Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes.
        J Pharmacol Exp Ther. 1994; 271: 1630-1637
        • Bart G.
        • Schluger J.H.
        • Borg L.
        • Ho A.
        • Bidlack J.M.
        • Kreek M.J.
        Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity?.
        Neuropsychopharmacology. 2005; 30: 2254-2262
        • Wee S.
        • Koob G.F.
        The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.
        Psychopharmacology (Berl). 2010; 210: 121-135
        • Solomon R.L.
        • Corbit J.D.
        An opponent-process theory of motivation: I. Temporal dynamics of affect.
        Psychol Rev. 1974; 81: 119-145
        • Yan F.
        • Roth B.L.
        Salvinorin A: A novel and highly selective kappa-opioid receptor agonist.
        Life Sci. 2004; 75: 2615-2619
        • Zhang Y.
        • Butelman E.R.
        • Schlussman S.D.
        • Ho A.
        • Kreek M.J.
        Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.
        Psychopharmacology (Berl). 2004; 172: 422-429
        • Walker B.M.
        • Koob G.F.
        Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
        Neuropsychopharmacology. 2008; 33: 643-652
        • Walker B.M.
        • Valdez G.R.
        • McLaughlin J.P.
        • Bakalkin G.
        Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.
        Alcohol. 2012; 46: 359-370
        • Walker B.M.
        • Zorrilla E.P.
        • Koob G.F.
        Systemic kappa-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats.
        Addict Biol. 2011; 16: 116-119
        • Lindholm S.
        • Ploj K.
        • Franck J.
        • Nylander I.
        Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain.
        Alcohol. 2000; 22: 165-171
        • Lindholm S.
        • Rosin A.
        • Dahlin I.
        • Georgieva J.
        • Franck J.
        Ethanol alters the effect of kappa receptor ligands on dopamine release in the nucleus accumbens.
        Physiol Behav. 2007; 92: 167-171
        • Przewlocka B.
        • Turchan J.
        • Lason W.
        • Przewlocki R.
        Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens.
        Neurosci Lett. 1997; 238: 13-16
        • Taqi M.M.
        • Bazov I.
        • Watanabe H.
        • Sheedy D.
        • Harper C.
        • Alkass K.
        • et al.
        Prodynorphin CpG-SNPs associated with alcohol dependence: elevated methylation in the brain of human alcoholics.
        Addict Biol. 2011; 16: 499-509
        • Sarkisyan D.
        • Hussain M.Z.
        • Watanabe H.
        • Kononenko O.
        • Bazov I.
        • Zhou X.W.
        • et al.
        Downregulation of the endogenous opioid peptides in the dorsal striatum of human alcoholics.
        Front Cell Neurosci. 2015; 9: 187
        • Marxen M.
        • Gan G.
        • Schwarz D.
        • Mennigen E.
        • Pilhatsch M.
        • Zimmermann U.S.
        • et al.
        Acute effects of alcohol on brain perfusion monitored with arterial spin labeling magnetic resonance imaging in young adults.
        J Cereb Blood Flow Metab. 2014; 34: 472-479
        • Strang N.M.
        • Claus E.D.
        • Ramchandani V.A.
        • Graff-Guerrero A.
        • Boileau I.
        • Hendershot C.S.
        Dose-dependent effects of intravenous alcohol administration on cerebral blood flow in young adults.
        Psychopharmacology (Berl). 2015; 232: 733-744
        • Tolentino N.J.
        • Wierenga C.E.
        • Hall S.
        • Tapert S.F.
        • Paulus M.P.
        • Liu T.T.
        • et al.
        Alcohol effects on cerebral blood flow in subjects with low and high responses to alcohol.
        Alcoholism Clin Experimental Research. 2011; 35: 1034-1040
        • Lingford-Hughes A.R.
        • Acton P.D.
        • Gacinovic S.
        • Suckling J.
        • Busatto G.F.
        • Boddington S.J.
        • et al.
        Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy.
        Br J Psychiatry. 1998; 173: 116-122
        • Erritzoe D.
        • Tziortzi A.
        • Bargiela D.
        • Colasanti A.
        • Searle G.E.
        • Gunn R.N.
        • et al.
        In vivo imaging of cerebral dopamine D3 receptors in alcoholism.
        Neuropsychopharmacology. 2014; 39: 1703-1712